Cargando…

Biomarkers in Multiple Sclerosis: Role of Antibodies

The first international workshop on “Biomarkers in Multiple Sclerosis” was organized by B. Bielekova, R. Hohlfeld, R. Martin and U. Utz from April 14–16, 2004, in Washington, DC. The workshop intended to discuss the current status and potential applicability of biological markers for the understandi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, Thomas, Reindl, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2006
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851391/ https://www.ncbi.nlm.nih.gov/pubmed/17124342 http://dx.doi.org/10.1155/2006/602103

Ejemplares similares

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Chemokine Receptors as Biomarkers in Multiple Sclerosis
por: Fox, Robert J., et al.
Publicado: (2006)

Biomarkers Indicative of Blood-Brain Barrier Disruption in Multiple Sclerosis
por: Waubant, Emmanuelle
Publicado: (2006)

Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers
por: O’Connor, Kevin C., et al.
Publicado: (2006)

Antibody signatures in patients with histopathologically defined multiple sclerosis patterns
por: Stork, Lidia, et al.
Publicado: (2020)

Treatment of Cognitive Impairment in Multiple Sclerosis
por: Pierson, Susan H., et al.
Publicado: (2006)

Serum Levels of Anti-Myelin Antibodies in Relapsing-Remitting Multiple Sclerosis Patients during Different Phases of Disease Activity and Immunomodulatory Therapy
por: Angelucci, Francesco, et al.
Publicado: (2005)

Risk of Multiple Sclerosis in Epstein–Barr Virus Infection
por: Ahmed, Syed Ijlal, et al.
Publicado: (2019)

Molecular Network Analysis of T-Cell Transcriptome Suggests Aberrant Regulation of Gene Expression by NF-κB As a Biomarker for Relapse of Multiple Sclerosis
por: Satoh, Jun-ichi, et al.
Publicado: (2008)

Depression and Cognitive Impairment in Disability-Free Early Multiple Sclerosis
por: Haase, Claus G., et al.
Publicado: (2003)

Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis
por: Ehling, Rainer, et al.
Publicado: (2011)

The Role of Antibodies in the Pathogenesis of Multiple Sclerosis
por: Yu, Xiaoli, et al.
Publicado: (2020)

KIR4.1 Antibodies as Biomarkers in Multiple Sclerosis
por: Wunsch, Marie, et al.
Publicado: (2014)

Antibodies to neurofilament light as potential biomarkers in multiple sclerosis
por: Puentes, Fabiola, et al.
Publicado: (2021)

Cerebrospinal Fluid B Cells Correlate with Early Brain Inflammation in Multiple Sclerosis
por: Kuenz, Bettina, et al.
Publicado: (2008)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Oxidative Stress is Increased in Serum from Mexican Patients with Relapsing-Remitting Multiple Sclerosis
por: Ortiz, Genaro Gabriel, et al.
Publicado: (2009)

Decrease of Mutual Information in Brain Electrical Activity of Patients with Relapsing-Remitting Multiple Sclerosis
por: Lenne, Bruno, et al.
Publicado: (2013)

Two Potential Biomarkers Identified in Mesenchymal Stem Cells and Leukocytes of Patients with Sporadic Amyotrophic lateral Sclerosis
por: Nachmany, Henny, et al.
Publicado: (2012)

Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study
por: Wurth, Sebastian, et al.
Publicado: (2017)

Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study
por: Bsteh, Gabriel, et al.
Publicado: (2016)

New Markers of Early Cardiovascular Risk in Multiple Sclerosis Patients: Oxidized-LDL Correlates with Clinical Staging
por: Palavra, Filipe, et al.
Publicado: (2013)

Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
por: Nosher, Sadia, et al.
Publicado: (2021)

Biomarkers in Multiple Sclerosis
por: Martin, Roland, et al.
Publicado: (2006)

Basic CSF parameters and MRZ reaction help in differentiating MOG antibody-associated autoimmune disease versus multiple sclerosis
por: Vlad, Benjamin, et al.
Publicado: (2023)

Association between the Endogenous Retrovirus HRES-1 and Multiple Sclerosis in the United Kingdom – Evidence of Genetically Different Disease Subsets?
por: Rasmussen, H. B., et al.
Publicado: (2000)

Viral antibodies in multiple sclerosis
por: Ferrante, P., et al.
Publicado: (1982)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Digital Biomarkers in Multiple Sclerosis
por: Dillenseger, Anja, et al.
Publicado: (2021)

Protein biomarkers in multiple sclerosis
por: Kim, Jun-Soon
Publicado: (2023)

Lack of Association between PRNP M129V Polymorphism and Multiple Sclerosis, Mild Cognitive Impairment, Alcoholism and Schizophrenia in a Korean Population
por: Choi, Ihn-Geun, et al.
Publicado: (2010)

Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review
por: Krajnc, Nik, et al.
Publicado: (2021)

Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
por: Krajnc, Nik, et al.
Publicado: (2022)

Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
por: Clemente, Nausicaa, et al.
Publicado: (2017)

MOG antibody-associated diseases
por: Reindl, Markus, et al.
Publicado: (2015)

Antineutrophil Cytoplasmic Antibody and Multiple Sclerosis
por: George, Jason C., et al.
Publicado: (2017)

Inflammation-related plasma and CSF biomarkers for multiple sclerosis
por: Huang, Jesse, et al.
Publicado: (2020)

Guilty by association? SARS‐CoV‐2 antibodies and myelin oligodendrocyte glycoprotein antibody‐associated disease
por: Tanasescu, Radu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3fbaol441fj10i5uken571eb92